The Role of the PAX8/PPARFusion Oncogene in Thyroid Cancer
Open Access
- 29 October 2008
- journal article
- review article
- Published by Hindawi Limited in PPAR Research
- Vol. 2008, 1-10
- https://doi.org/10.1155/2008/672829
Abstract
Thyroid cancer is uncommon and exhibits relatively low mortality rates. However, a subset of patients experience inexorable growth, metastatic spread, and mortality. Unfortunately, for these patients, there have been few significant advances in treatment during the last 50 years. While substantial advances have been made in recent years about the molecular genetic events underlying papillary thyroid cancer, the more aggressive follicular thyroid cancer remains poorly understood. The recent discovery of the PAX8/PPAR translocation in follicular thyroid carcinoma has promoted progress in the role of PPAR as a tumor suppressor and potential therapeutic target. The PAX8/PPAR fusion gene appears to be an oncogene. It is most often expressed in follicular carcinomas and exerts a dominant-negative effect on wild-type PPAR, and stimulates transcription of PAX8-responsive promoters. PPAR agonists have shown promising results in vitro, although very few studies have been conducted to assess the clinical impact of these agents.Keywords
Funding Information
- National Institutes of Health (CA080117)
This publication has 76 references indexed in Scilit:
- PAX8PPARγ Stimulates Cell Viability and Modulates Expression of Thyroid-Specific Genes in a Human Thyroid Cell LineThyroid®, 2007
- PAX8-PPARγ Rearrangement Is Frequently Detected in the Follicular Variant of Papillary Thyroid CarcinomaJournal of Clinical Endocrinology & Metabolism, 2006
- PPARγ insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-κB signaling pathwayOncogene, 2005
- Effect of peroxisome proliferator-activated receptor γ agonist, rosiglitazone, on dedifferentiated thyroid cancersNuclear Medicine Communications, 2004
- The PAX8/PPARγ fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARγ inhibitionOncogene, 2004
- Molecular Profile and Clinical-Pathologic Features of the Follicular Variant of Papillary Thyroid Carcinoma: An Unusually High Prevalence of ras MutationsAmerican Journal of Clinical Pathology, 2003
- Overexpression of Cyclin D1 and Underexpression of p27 Predict Lymph Node Metastases in Papillary Thyroid CarcinomaJournal of Clinical Endocrinology & Metabolism, 2002
- Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cellsFEBS Letters, 1999
- Deletion of 3p25→pter in a primary follicular thyroid carcinoma and its metastasisGenes, Chromosomes and Cancer, 1993
- The mRNA levels of thyrotropin receptor, thyroglobulin and thyroid peroxidase in neoplastic human thyroid tissuesBiochemical and Biophysical Research Communications, 1991